Latest Oncotype DX Stories
Landmark Study Reconfirms Oncotype DX® Stratifies DCIS Patient Risk REDWOOD CITY, Calif., Dec. 2, 2014 /PRNewswire/ -- Genomic Health, Inc.
REDWOOD CITY, Calif., Nov. 26, 2014 /PRNewswire/ -- Genomic Health, Inc.
These Studies and Genomic Health's First Liquid Biopsy Study in Bladder Cancer To Be Presented at 2014 Society of Urologic Oncology Annual Meeting, December 3-5 REDWOOD CITY, Calif., Nov.
9% Increase in Test Volume; 5% Increase in Total Revenue REDWOOD CITY, Calif., Nov.
REDWOOD CITY, Calif., Nov. 4, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
REDWOOD CITY, Calif., Oct. 28, 2014 /PRNewswire/ -- Genomic Health, Inc.
Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif., Sept.
Prostate Cancer Survivor Joe Torre, Three Prominent Advocacy Organizations and Genomic Health Partner to Encourage Men to Seek Genomic Testing to Enable More Confident Treatment Decisions and Avoid
Results Suggest that Oncotype DX® Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being REDWOOD CITY, Calif., Sept.